Exclusive Summary

• - Fully off-patent and multisource globally, best positioned for distribution in EU (select markets), CIS, LATAM, MENA and APAC rather than the US.
• - Targets large, recurrent demand: roughly 10–12 million chemo cycles and 60–90 million surgical patients per year need antiemetic prophylaxis.
• - As a 5‑HT3 RA, it aligns with international guidelines as a first-line/standard component for CINV and a primary option for PONV in cost‑sensitive settings.
• - With EU‑GMP/WHO‑GMP, complete CTD, long shelf life and flexible packs, distributors can shorten registration and tender lead times.
• - Clear cost edge versus originator and palonosetron enables rapid uptake in price‑driven tenders and hospital channels.